Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
CME/CE
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
0.25 credits
- Mikhail Kosiborod, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.25 credits
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
CME/CE
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
- Mazen Hanna, MD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Heart Matters
No benefit of routine spironolactone post-MI
- Sanjit Jolly, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Heart Matters
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Heart Matters
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Heart Matters
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Heart Matters
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
- Léna Rivard, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

Programs

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Matters
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Heart Matters
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Heart Matters
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
- Chisato Izumi, MD, PhD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Scott Solomon, MD
- Mikhail Kosiborod, MD
0.50 credits
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
MinuteCE®
Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression
0.75 program credits
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Neil Skolnik, MD
- Karina Brown, BSN, RN
0.75 program credits
MinuteCE®
Optimizing Heart Failure Management
0.75 credits 5 episodes
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Neil Skolnik, MD
- Trina Huynh, PharmD
- Jessica Lin, MPAP
- Melissa Mclenon, DNP, ACNP-BC
- Karina Brown, BSN, RN
0.75 credits 5 episodes

Clinical Practice

Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
- John Russell, MD
- Noel Dasgupta, MD, FACC
- Sami Khella, MD
0.50 credits
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
Heart Matters
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Heart Matters
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
How Artificial Sweeteners Could Be Linked to Heart Disease
How Artificial Sweeteners Could Be Linked to Heart Disease
Heart Matters
How Artificial Sweeteners Could Be Linked to Heart Disease
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Wilson Tang, MD
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
MinuteCE®
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
1.75 program credits
- Scott Kaatz, DO, MSc, FACP, SFHM
1.75 program credits
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
MinuteCE®
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
1.75 program credits
- Deborah Siegal, MD, MSc, FRCPC
1.75 program credits
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
MinuteCE®
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
1.75 program credits
- Alfonso J. Tafur, MD, MS, MBA, RPVI
1.75 program credits
Right from the Onset: PE Diagnosis, Management
Right from the Onset: PE Diagnosis, Management
MinuteCE®
Right from the Onset: PE Diagnosis, Management
1.75 program credits
- Bruce L. Davidson, MD, MPH
1.75 program credits

CME

Partnering with Patients: Building Effective Communication and Support in HF Care
Partnering with Patients: Building Effective Communication and Support in HF Care
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 program credits
- Brian P. McDonough, MD, FAAFP
- Barry Greenberg, MD
- Melissa Mclenon, DNP, ACNP-BC
0.75 program credits
A Practical Guide to Prescribing in HF
A Practical Guide to Prescribing in HF
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 program credits
- Neil Skolnik, MD
- Barry Greenberg, MD
- Trina Huynh, PharmD
- Melissa Mclenon, DNP, ACNP-BC
0.75 program credits
Level Up Your Skills: Tailoring Management of HF
Level Up Your Skills: Tailoring Management of HF
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 program credits
- Neil Skolnik, MD
- Barry Greenberg, MD
- Trina Huynh, PharmD
- Jessica Lin, MPAP
- Melissa Mclenon, DNP, ACNP-BC
- Karina Brown, BSN, RN
0.75 program credits
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
MinuteCE®
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
1.75 program credits
- Deborah Siegal, MD, MSc, FRCPC
1.75 program credits
Case Time! VTE Prophylaxis Post Hip Replacement
Case Time! VTE Prophylaxis Post Hip Replacement
MinuteCE®
Case Time! VTE Prophylaxis Post Hip Replacement
1.75 program credits
- Victor F. Tapson, MD
1.75 program credits
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
MinuteCE®
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
1.75 program credits
- Scott Kaatz, DO, MSc, FACP, SFHM
1.75 program credits
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE
MinuteCE®
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE
1.75 program credits
- Bruce L. Davidson, MD, MPH
- Victor F. Tapson, MD
1.75 program credits
Case Study - New Guideline Recommendations into Clinical Practice for the Patient with AF
Case Study - New Guideline Recommendations into Clinical Practice for the Patient with AF
MinuteCE®
Case Study - New Guideline Recommendations into Clinical Practice for the Patient with AF
1.00 program credit
- Manesh R. Patel, MD
1.00 program credit